Exhibit 99.1
NexImmune Reports Second Quarter 2021 Financial Results and Provides Business Updates
| • | Announcing first solid tumor indication in HPV associated-malignancies – NEXI-003 |
| • | Advancing two lead product candidates in Phase 1/2 clinical trials |
| • | Additional clinical and preclinical data anticipated in the second half of 2021 |
GAITHERSBURG, Md., August 9, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today reported its financial results for the second quarter of 2021.
“The first half of the year was a very productive period for the company. We are focused on completing enrollment in our Phase I/II clinical trials for NEXI-001 and NEXI-002 and expect to present additional clinical data for each during scientific conferences toward the end of this year,” said Scott Carmer, Chief Executive Officer. “We are also excited to announce our first indication in solid tumors and expect to submit our IND for HPV-associated malignancies in the second quarter of 2022. Additionally, we’ve initiated IND-enabling pre-clinical experiments that will be the basis for multiple IND submissions in support of our injectable nanoparticle (AIM INJ). This progress highlights the promise of our AIM platform across disease areas and delivery modalities, and we look forward to providing further updates on these important programs later this year.”
Select 2Q 2021 Clinical and Business Highlights
Clinical and Preclinical Updates
NEXI-001
| • | Abstract presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting in June 2021 highlights safety, tolerability, immune responses and early clinical activity in all patients evaluated |
| • | Dose Level 2 (single infusion of 200M cells/month x two cycles) is fully enrolled |
| • | Dose Level 3 (single infusion of 200M cells/week for three weeks x two cycles) is enrolling |
| • | Treatment-related adverse events, including infusion reactions, GVHD, CRS, and neurotoxicity (ICANS), have not been observed in patients who received NEXI-001 at Dose Level 1 and Dose Level 2, either as single or repeat infusions |
| • | Further data expected to be announced during the American Society of Hematology (ASH) Annual Meeting in December 2021 |
NEXI-002
| • | Abstract presented at European Hematology Association Annual Meeting in May 2021 highlights safety, tolerability and immune responses in all patients evaluated |
| • | Safety cohort completed and expansion phase is enrolling |
| • | Treatment-related adverse events, including infusion reactions, CRS, and neurotoxicity (ICANS), have not been observed in patients who received NEXI-002 |
| • | Further data expected to be announced during the American Society of Hematology (ASH) Annual Meeting in December 2021 |
NEXI-003
| • | First solid tumor clinical trial for multi-antigen autologous AIM ACT product will target HPV-associated malignancies |
| • | Preclinical data validating the selection of multiple immunogenic HPV antigen peptides expected to be announced during the Society for Immunotherapy of Cancer’s Annual Meeting (SITC 2021) in November 2021 |
| • | Investigational new drug (IND) submission planned for 2Q 2022 |
Other R&D
| • | IND enabling preclinical studies for the AIM INJ platform continue; abstract presentations planned for SITC 2021 in November 2021 |
| • | First collaboration in autoimmune diseases announced with Yale University to evaluate AIM INJ nanoparticles in Type 1 diabetes |
Business Updates
| • | Announced formation of the company’s Scientific Advisory Board |
| • | Announced the appointments of Dr. Jack Ragheb, SVP, Translational Medicine, and Matthew Schiller, Head of Business Development |
Select 2Q 2021 Financial Highlights
Cash, cash equivalents and marketable securities for the company as of June 30, 2021 were $102.8M compared to $118.1M for quarter ending March 31, 2021. Based upon current operating plans, NexImmune expects that its existing cash, cash equivalents and marketable securities will enable the company to fund its operating and capital expenditure requirements through the third quarter of 2022.
Research and development expenses were $8.1M in the second quarter of 2021, compared to $4.2M for the same period in the prior year. The increase in R&D
expenses was mainly attributable to costs for the two clinical trials, as well as personnel-related expenses driven by increased headcount.
General and administrative expenses were $4.0M, compared to $2.6M for the same period the prior year. The increase was due primarily to increases in headcount and fees related to professional and consulting services.
Net loss, according to generally accepted accounting principles in the U.S. (GAAP), was $12.2M for the quarter, or a basic and diluted GAAP loss per share of $0.54. This compared to a net loss of $6.9M, or a basic and diluted GAAP loss per share of $6.17, for the same period the prior year.
About NexImmune
NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune’s approach is a proprietary Artificial Immune Modulation (AIM™) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities.
NexImmune’s two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to 3 or more prior lines of therapy, respectively. NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease.
For more information, visit www.neximmune.com.
Forward Looking Statements
This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NexImmune, Inc. (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning our results of operations for the six months ended June 30, 2021; the sufficiency of the Company’s current cash, cash equivalents and marketable securities to fund its planned operations through the third quarter of 2022; our planned and ongoing clinical studies for the Company’s product candidates, including NEXI-001, NEXI-002 and NEXI-003; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; and the utility of prior preclinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission (“SEC”) on March 31, 2021, and subsequent reports that we file with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.
NEXIMMUNE, INC.
BALANCE SHEETS
| June 30, 2021 |
December 31, 2020 |
|||||||
| (unaudited) | ||||||||
| ASSETS |
||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 63,816,106 | $ | 5,031,079 | ||||
| Marketable securities |
38,979,670 | — | ||||||
| Restricted cash |
67,500 | 67,500 | ||||||
| Prepaid expenses and other current assets |
8,327,117 | 3,293,858 | ||||||
|
|
|
|
|
|||||
| Total current assets |
111,190,393 | 8,392,437 | ||||||
| Property and equipment, net |
4,148,875 | 2,885,260 | ||||||
| Other non-current assets |
53,373 | 23,373 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 115,392,641 | $ | 11,301,070 | ||||
|
|
|
|
|
|||||
| LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) |
||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ | 2,169,660 | $ | 2,760,129 | ||||
| Accrued expenses |
2,469,942 | 2,603,027 | ||||||
| Derivative liability |
— | 1,702,359 | ||||||
| Other current liabilities |
843,619 | 843,619 | ||||||
| Convertible notes issued to related parties |
— | 7,324,267 | ||||||
| Convertible notes |
— | 11,793,397 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
5,483,221 | 27,026,798 | ||||||
|
|
|
|
|
|||||
| Deferred rent, net of current portion |
23,529 | |||||||
| Other non-current liabilities |
— | 4,935 | ||||||
|
|
|
|
|
|||||
| Total liabilities |
5,483,221 | 27,055,262 | ||||||
|
|
|
|
|
|||||
| Commitments and contingencies |
||||||||
| Redeemable convertible preferred stock |
||||||||
| Series A Redeemable Convertible Preferred Stock, $0.0001 par value, no shares outstanding as of June 30, 2021 and 121,735,303 shares authorized, issued and outstanding as of December 31, 2020. Liquidation value of $42,314,789 as of December 31, 2020. |
— | 35,047,435 | ||||||
| Series A-2 Redeemable Convertible Preferred Stock, $0.0001 par value, no shares outstanding as of June 30, 2021 and 28,384,899 shares authorized, 22,047,361 shares issued and outstanding as of December 31, 2020. Liquidation value of $8,683,746 as of December 31, 2020. |
— | 7,685,865 | ||||||
| Series A-3 Redeemable Convertible Preferred Stock, $0.0001 par value, no shares outstanding as of June 30, 2021 and 34,061,879 shares authorized, 31,209,734 shares issued and outstanding as of December 31, 2020. Liquidation value of $11,699,176 as of December 31, 2020. |
— | 10,887,449 | ||||||
|
|
|
|
|
|||||
| Total redeemable convertible preferred stock |
— | 53,620,749 | ||||||
| Stockholders’ equity (deficit) |
||||||||
| Common Stock, $0.0001 par value, 250,000,000 shares authorized, 22,628,007 issued and outstanding as of June 30, 2021 and 1,256,609 shares issued and outstanding as of December 31, 2020. |
2,263 | 126 | ||||||
| Additional paid-in-capital |
207,480,819 | 8,206,938 | ||||||
| Accumulated other comprehensive loss |
(2,917 | ) | — | |||||
| Accumulated deficit |
(97,570,745 | ) | (77,582,005 | ) | ||||
|
|
|
|
|
|||||
| Total stockholders’ equity (deficit) |
109,909,420 | (69,374,941 | ) | |||||
|
|
|
|
|
|||||
| Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) |
$ | 115,392,641 | $ | 11,301,070 | ||||
|
|
|
|
|
|||||
NEXIMMUNE, INC.
STATEMENTS OF OPERATIONS
(unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Revenue |
$ | — | $ | — | $ | — | $ | — | ||||||||
| Operating expenses: |
||||||||||||||||
| Research and development |
8,124,973 | 4,209,261 | 14,137,581 | 8,481,428 | ||||||||||||
| General and administrative |
4,038,050 | 2,565,402 | 8,095,642 | 4,653,803 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
12,163,023 | 6,774,663 | 22,233,223 | 13,135,231 | ||||||||||||
| Loss from operations |
(12,163,023 | ) | (6,774,663 | ) | (22,233,223 | ) | (13,135,231 | ) | ||||||||
| Other (expense) income: |
||||||||||||||||
| Interest income |
6,851 | 1,184 | 10,464 | 19,868 | ||||||||||||
| Interest expense |
(101 | ) | (183,682 | ) | (904,220 | ) | (184,671 | ) | ||||||||
| Change in fair value of derivative liability |
— | — | 2,424,877 | — | ||||||||||||
| Other (expense) income |
(25,974 | ) | 26,636 | (26,696 | ) | 54,001 | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Other (expense) income |
(19,224 | ) | (155,862 | ) | 1,504,425 | (110,802 | ) | |||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net Loss |
$ | (12,182,247 | ) | $ | (6,930,525 | ) | $ | (20,728,798 | ) | $ | (13,246,033 | ) | ||||
| Accumulated dividends on Redeemable Convertible Preferred Stock |
— | (815,816 | ) | (377,562 | ) | $ | (1,631,632 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss attributable to common stockholders |
$ | (12,182,247 | ) | $ | (7,746,341 | ) | $ | (21,106,360 | ) | $ | (14,877,665 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Basic and diluted net loss attributable to common stockholders per common share |
$ | (0.54 | ) | $ | (6.17 | ) | $ | (1.20 | ) | $ | (11.86 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Basic and diluted weighted-average number of common shares outstanding |
22,608,866 | 1,254,681 | 17,648,551 | 1,254,681 | ||||||||||||
STATEMENTS OF COMPREHENSIVE LOSS
(unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Net loss |
$ | (12,182,247 | ) | $ | (6,930,525 | ) | $ | (20,728,798 | ) | $ | (13,246,033 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Other comprehensive loss: |
||||||||||||||||
| Unrealized (loss) gain on available-for-sale marketable securities, net of tax |
(2,917 | ) | — | (2,917 | ) | (506 | ) | |||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Comprehensive loss |
$ | (12,185,164 | ) | $ | (6,930,525 | ) | $ | (20,731,715 | ) | $ | (13,246,539 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
Contacts
Investors:
Chad Rubin, SVP Corporate Affairs
NexImmune, Inc.
646.319.3261
crubin@neximmune.com
Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
mikebeyer@sambrown.com
